来源：生物谷 2012-10-24 08:20
2012年10月17日 讯 /生物谷BIOON/ --近日，墨尔本研究人员已经开发出一种牛奶能用来保护人类免受艾滋病毒的感染。
全球范围内约30亿人感染了艾滋病毒，目前并没有有效的疫苗。新研究发现牛奶中含有抵御人类免疫缺陷病毒（HIV）的抗体。
墨尔本大学博士Marit Kramski和他的同事发现，使用奶牛产生抑制HIV-抗体比现有的疫苗生产方法更便宜。他们曾与澳大利亚生物技术公司Immuron有限公司开发此类牛奶。科学家们给孕牛接种艾滋病毒蛋白疫苗，奶牛第一次分娩后产出的牛奶中含有抵御人类免疫缺陷病毒（HIV）的抗体。
Marit表示：现在我们能收获含有能作用于艾滋病毒表面蛋白的特异性抗体的牛奶。 我们已经测试了这些抗体，发现这些抗体能结合艾滋病毒，抑制病毒感染和进入人体细胞。（生物谷：Bioon.com）
Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 Envelope with potential use in microbicides.
Marit Kramski, Rob J. Center, Adam K. Wheatley, Jonathan C. Jacobson, Marina R. Alexander, Grant Rawlin and Damian F.J. Purcell#
Bovine colostrum (first milk) contains very high concentrations of IgG and on average 1 kg (500 g/L) of IgG can be harvested from each immunized cow immediately after calving. We used a modified vaccination strategy together with established production systems from the dairy-food industry for the large-scale manufacture of broadly neutralizing HIV-1 IgG. This approach provides a low-cost mucosal HIV preventive agent potentially suitable for a topical microbicide. Four cows were vaccinated pre- and/or post-conception with recombinant HIV-1 gp140 envelope (Env) oligomers of clade B or A, B and C. Colostrum and purified-colostrum IgG were assessed for cross-clade binding and neutralization against a panel of 27 Env-pseudotyped reporter viruses. Vaccination elicited high anti-gp140 IgG titers in serum and colostrum with reciprocal endpoint titers of up to 1x105. While non-immune colostrum showed some intrinsic neutralizing activity, colostrum from 2 cows receiving a longer duration vaccination regimen demonstrated broad HIV-1 neutralizing activity. Colostrum-purified polyclonal IgG retained gp140-reactivity and neutralization activity and blocked the binding of the b12 monoclonal antibody to gp140, showing specificity for the CD4 binding site. Colostrum derived anti-HIV antibodies offer a cost-effective option for preparing the substantial quantities of broadly neutralizing antibodies that would be needed in a low-cost topical combination HIV-1 microbicide.
黄热病毒特异性抗体研究获进展
APP专享
Nat Biotech：DNA检测能够判断抗体的有效性
APP专享
Cell Host & Microbe：试验性“抗体鸡尾酒”疗法可用于治疗埃博拉病毒感染
APP专享
首个DNA编码的单克隆抗体疗法有望进入临床试验
APP专享
遗传性骨病新药！协和发酵麒麟重磅FGF-23靶向抗体药物Crysvita在日本提交上市申请
APP专享
全球首个纳米抗体药物！赛诺菲Cablivi治疗罕见血栓疾病aTTP的III期数据发表NEJM
APP专享
Viela Bio自身免疫病抗体疗法2期结果积极
APP专享
岸迈生物双特异性抗体中美双报IND几乎同步获批
APP专享
药明生物与正大天晴达成双特异性抗体开发合作
APP专享
抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批
APP专享
在线课堂 Webinar